Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

134.37 +0.14 (+0.10%)

Streaming Delayed Price Updated: 9:52 AM EDT, Aug 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗

August 05, 2026

There is no end in sight for the drugmaker's dividend growth streak.

Via The Motley Fool

Topics Intellectual Property

Should You Buy AbbVie Stock Hand Over Fist Before July 31? ↗

July 27, 2026

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

Via The Motley Fool

Topics Earnings Intellectual Property

Why Wall Street Can't Get Enough of This Dividend King ↗

July 25, 2026

AbbVie has an attractive 2.7% yield, a solid pharmaceutical business, and is clearly focused on its dividend.

Via The Motley Fool

Topics Intellectual Property

Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗

May 11, 2026

Via Chartmill

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow ↗

July 21, 2026

It looks like a great buy-and-hold option.

Via The Motley Fool

Topics Intellectual Property

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend? ↗

July 19, 2026

There's no need to panic.

Via The Motley Fool

My 2 Favorite Dividend Kings to Buy Right Now ↗

July 19, 2026

They can help stabilize your portfolio in these otherwise volatile times.

Via The Motley Fool

Topics Intellectual Property

What This Apogee Insider Move Might Mean After a 247% Stock Run ↗

July 12, 2026

Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift.

Via The Motley Fool

Topics Regulatory Compliance

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗

July 11, 2026

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

Via The Motley Fool

Topics Intellectual Property

The Dividend ETF Quietly Outperforming the S&P 500 ↗

July 07, 2026

This dividend ETF's focus beyond yield continues to pay off for investors.

Via The Motley Fool

Topics ETFs Stocks

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗

June 30, 2026

AbbVie knows how to plan ahead.

Via The Motley Fool

Topics Intellectual Property

In today's session, these stocks are experiencing unusual volume. ↗

June 23, 2026

Via Chartmill

Why AbbVie Stock Jumped Today ↗

June 22, 2026

An intriguing acquisition could bring exciting new drugs into the medicine maker's development pipeline.

Via The Motley Fool

AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗

June 22, 2026

The company is already renowned by many as a giant in the segment.

Via The Motley Fool

Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer ↗

June 22, 2026

On June 22, 2026, Apogee Therapeutics shares surged as investors reacted to AbbVie's proposed acquisition terms.

Via The Motley Fool

Topics Stocks

Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗

June 22, 2026

Via Chartmill

Which stocks are moving on Monday? ↗

June 22, 2026

Via Chartmill

Monday's session: gap up and gap down stocks ↗

June 22, 2026

Via Chartmill

These stocks that are showing activity before the opening bell on Monday. ↗

June 22, 2026

Via Chartmill

Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding ↗

June 10, 2026

Apogee Therapeutics (NASDAQ:APGE) executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the...

Via MarketBeat

Topics Initial Public Offering

Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗

June 04, 2026

Apogee Therapeutics (NASDAQ:APGE) executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic...

Via MarketBeat

Topics Initial Public Offering

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing...

Via MarketMinute

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors ↗

March 26, 2026

This biotech innovator in immunology reported a notable insider sale as its stock outperformed and drug development efforts continue.

Via The Motley Fool

Topics Regulatory Compliance

Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns

March 23, 2026

On March 23, 2026, the small-cap heavy Russell 2000 Index surged by a definitive 3.0%, soundly outperforming the S&P 500 and the Nasdaq Composite in a session characterized by aggressive "risk-on"...

Via MarketMinute

Topics ETFs Economy Stocks

Gapping stocks in Monday's session ↗

March 23, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 23, 2026

Via Chartmill

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.